ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache
This article was originally published in The Gray Sheet
Executive Summary
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.
You may also be interested in...
US Approvals Analysis: April A Big Month For Non-Invasive Neurostim
Two de novo go-aheads granted by FDA last month sent non-implantable neurostimulation devices to market, one for headaches and the other for tear production. Overall, the agency granted four de novos in April, continuing a strong trend this year for that marketing pathway, according to Medtech Insight's Approvals Tracker.
Self-Treat Vagus Nerve Stimulator Shows Promise For Cluster Headaches
A one-year open-label study published in Neurology suggests that electroCore’s gammaCore non-invasive vagus nerve stimulation system could be a practical therapy for chronic cluster headaches.
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.